Editors
Iwona Lugowska, MD, PhD
Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland
Professor Iwona Lugowska is Plenipotentiary Director for International Affairs, Head of the Early Phase Clinical Trials Unit, Leader of Centre of Excellence for Precision Oncology, Coordinator of the Centre for Research and Development and Consultant in Oncology in the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland.
Professor Lugowska is a board member of the European Organisation for Research and Treatment of Cancer (EORTC), Chair of the European Society for Medical Oncology (ESMO) Educational Publications Working Group and a member of the Ethics Committee at MSCI. She received an award from the American Society of Clinical Oncology (ASCO) IDEA Program 2010, visited the Memorial Sloan Kettering Cancer Center, New York (mentor, Robert Maki), and undertook a fellowship at the Sir Bobby Robson Cancer Trials Research Centre, Newcastle, UK (mentor, Ruth Plummer).
Her main fields of interest are sarcoma, melanoma research, immunotherapy, precision oncology and early phase clinical trials. She also developed a Clinical Support System for the management of gastrointestinal stromal tumour (GIST).
Jean-Yves Blay, MD, PhD
Centre Léon Bérard, Lyon; University Claude Bernard Lyon 1, Lyon; UNICANCER, Lyon, France
Professor Jean-Yves Blay is a medical oncologist, General Director of the Centre Léon Bérard, the Comprehensive Cancer Centre of Lyon, France, researcher and a Professor at the University Claude Bernard, France. Since 2019, he has been the President of the French Federation of Cancer Centres: UNICANCER.
His work focuses on sarcoma, genomics and targeted treatment of cancer, immuno-oncology and the relationship between tumour immunological microenvironment and malignant cells, with the goal of clinical applications in the field of diagnosis, prognosis and treatment.
Professor Blay has been the Director of the LYriCAN SIRIC (previously LYRIC) since 2018. He has also been President of the French Sarcoma Group and Network Director of NETSARC+ network of sarcoma reference centres for the INCA since 2019. He serves as the Network Director of European Reference Network-EURACAN, designated by the EU Commission. Previously, he served as EORTC President (2009-2012). He has co-authored over 1000 peer-reviewed articles and book chapters and was distinguished as a Highly Cited Researcher in 2019.
Hans Gelderblom, MD, PhD
Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
Professor Dr Hans (André Johan) Gelderblom is Chair of the Department of Medical Oncology at Leiden University Medical Center (LUMC), Netherlands. His department has a research lab focused on the immunotherapy of cancer and his personal interests, aside from sarcoma, involve targeted therapy, pharmacokinetics and pharmacogenomics of cancer medication.
He is co-principal investigator of the Drug Rediscovery Protocol (DRUP trial), a nationwide study using approved matched targeted drugs off-label. He is Chair of the EORTC Soft Tissue and Bone Sarcoma group and member of the Dutch Committee of Bone Tumours. LUMC is a national and European reference centre for GIST, bone and soft tissue sarcoma and has an established oncology bench-to-bedside infrastructure and track record.
Professor Gelderblom has co-authored approximately 400 papers, of which more than 200 are in the field of GIST and sarcoma. His personal aim is to improve the outcome for patients with these rare tumours.
Contributors
C Bergeron
IHOPE/ Centre Léon Bérard, Lyon, France
S Bielack
Klinikum Stuttgart – Olgahospital, Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany
J-Y Blay
Centre Léon Bérard, Lyon; University Claude Bernard Lyon 1, Lyon; UNICANCER, Lyon, France
JVMG Bovée
Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
AHG Cleven
Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
N Corradini
IHOPE/ Centre Léon Bérard, Lyon, France
G Decanter
Surgical Oncology Department, Centre Oscar Lambret, Lille, France
H Gelderblom
Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
SJ Harris
Bendigo Cancer Centre, Bendigo, Victoria, Australia
N Hindi
Medical Oncology Department, University Hospital Virgen del Rocio, Seville; Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Seville, Spain
P Hohenberger
Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Heidelberg, Germany
H Joensuu
Department of Oncology, Helsinki University Hospital, Helsinki; University of Helsinki, Helsinki, Finland
I Judson
The Institute of Cancer Research, London, UK
A Lipplaa
Department of Medical Oncology Leiden University Medical Center, Leiden, Netherlands
I Lugowska
Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland
J Martin-Broto
Medical Oncology Department, University Hospital Virgen del Rocio, Seville; Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Seville, Spain
Y McGovern
Chelsea & Westminster Hospital NHS Foundation Trust, London, UK
N Penel
Medical Oncology Department, Centre Oscar Lambret, Lille; Lille University, Lille, France
G Pentheroudakis
Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece
P Rutkowski
Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland
S Stacchiotti
Adult Mesenchymal Tumor Medical Therapy Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
N Vassos
Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Heidelberg, Germany
G Zarkavelis
Department of Medical Oncology, University of Ioannina, Ioannina, Greece
Declarations of interest
C Bergeron: Nothing to declare.
S Bielack: Consultancy/advisory board: Bayer, Boehringer Ingelheim, Clinigen, Ipsen, Isofol, Lilly, Pfizer, Novartis, Roche, Sensorion; Principal Investigator (Germany) for LOXO-TRK-15003 (Loxo, Bayer), E7080 (EISAI).
J-Y Blay: Has received research support and honoraria from Roche, Bayer, MSD, Deciphera, PharmaMar, GlaxoSmithKline, Novartis.
JVMG Bovée: No conflict of interest.
AHG Cleven: No conflict of interest.
N Corradini: Nothing to declare.
G Decanter: No conflict of interest.
H Gelderblom: No competing interests.
SJ Harris: No conflict of interest.
N Hindi: Honoraria: PharmaMar, Lilly; travel expenses: PharmaMar.
P Hohenberger: No conflict of interest.
H Joensuu: Has a co-appointment at Orion Pharma; fees from Neutron Therapeutics; stocks at Orion Pharma and Sartar Therapeutics.
I Judson: Has received honoraria from Lilly, Nektar, Bayer for attendance at advisory board meetings and Lilly for speaking at company-sponsored symposia.
A Lipplaa: No competing interests.
I Lugowska: Congress expenses: Roche.
J Martin-Broto: Advisory board: PharmaMar, Lilly, Bayer, Roche; research funds (for Institution): Lilly, Eisai, Novartis, PharmaMar, Pfizer, Celgene; travel expenses: PharmaMar.
Y McGovern: No conflict of interest.
N Penel: No conflict of interest.
G Pentheroudakis: No conflict of interest.
P Rutkowski: Has received honoraria for lectures and Advisory Board from Novartis, BMS, MSD, Pierre Fabre, Roche, Amgen, Blueprint Medicines.
S Stacchiotti: Research funds: Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer.
N Vassos: No conflict of interest.
G Zarkavelis: No conflict of interest.
